Vorapaxar in the secondary prevention of atherothrombotic events. - Wikidata - wikimedia - TriplyDB

Vorapaxar in the secondary prevention of atherothrombotic events.

Vorapaxar in the secondary prevention of atherothrombotic events.

http://www.wikidata.org/entity/Q34263311

about

Impact of selective platelet inhibition in reducing cardiovascular risk - role of vorapaxar State of the art: Oral antiplatelet therapy Vorapaxar: A novel agent to be considered in the secondary prevention of myocardial infarction Breaking boundaries-coagulation and fibrinolysis at the neurovascular interface Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis Adjunctive therapies to reduce thrombotic events in patients with a history of myocardial infarction: role of vorapaxar Future prospects for contact factors as therapeutic targets The role of atherectomy in the treatment of lower extremity peripheral artery disease Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar High-resolution crystal structure of human protease-activated receptor 1 Platelets and platelet adhesion molecules: novel mechanisms of thrombosis and anti-thrombotic therapies Blood thinners and gastrointestinal endoscopy Antiplatelet Therapy of Cilostazol or Sarpogrelate with Aspirin and Clopidogrel after Percutaneous Coronary Intervention: A Retrospective Cohort Study Using the Korean National Health Insurance Claim Database Pharmacokinetic drug evaluation of vorapaxar for secondary prevention after acute coronary syndrome.Management standards for stable coronary artery disease in India.Dual pathway therapy in acute coronary syndrome.State-of-the-Art: Hypo-responsiveness to oral antiplatelet therapy in patients with type 2 diabetes mellitus.Racial differences in human platelet PAR4 reactivity reflect expression of PCTP and miR-376c Hot topics in cardiology: data from IABP-SHOCK II, TRILOGY-ACS, WOEST, ALTIDUDE, FAME II and more.Platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trial: rationale and design.Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective.Differential signaling by protease-activated receptors: implications for therapeutic targeting.ANMCO/GICR-IACPR/SICI-GISE Consensus Document: the clinical management of chronic ischaemic cardiomyopathy Platelets and their chemokines in atherosclerosis-clinical applications.2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by repres The platelet: life on the razor's edge between hemorrhage and thrombosis.Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin.Proteinase-activated receptors in fibroproliferative lung disease.Abdominal aortic aneurysm in patients affected by intermittent claudication: prevalence and clinical predictors.Ankle/brachial index to everyone Endovascular treatment of lower extremity arteries is associated with an improved outcome in diabetic patients affected by intermittent claudication.Synthesis of indole derived protease-activated receptor 4 antagonists and characterization in human platelets Modulation of protease activated receptor 1 influences human metapneumovirus disease severity in a mouse model Reduction in overall occurrences of ischemic events with vorapaxar: results from TRACER.Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial.Parmodulins inhibit thrombus formation without inducing endothelial injury caused by vorapaxar.Evaluation of clinical risk factors to predict high on-treatment platelet reactivity and outcome in patients with stable coronary artery disease (PREDICT-STABLE).Antiplatelet therapy for peripheral arterial disease and critical limb ischemia: guidelines abound, but where are the data?Efficacy and safety of vorapaxar as approved for clinical use in the United States Current antiplatelet treatment strategy in patients with diabetes mellitus.

P2860

Q26745754-3319986E-C979-45C1-8B6D-96F83FE3EED4 Q26746161-1FCFBFA2-041F-4A58-B2EF-2B3DD01ED42A Q26748682-8E7DD104-38BE-4911-8F2B-282544BCB133 Q26781646-AEFCD2E8-6B16-4740-8A8D-4E9B8CB5EAE9 Q26783034-8057C574-6147-421D-AE5B-9057AFE7FA5A Q26801144-64EECF38-D96C-4E53-BD65-34B85CF8862A Q26865096-DECB385D-DF9D-49A8-99AE-B50CF0639672 Q27002637-0DD558DD-09BC-435C-9DAA-B1FC5C113509 Q27016071-1B7F9435-3149-4AC1-9E7D-8B8263FBEC62 Q27675402-CC614ABA-602D-42AE-9A4F-E498F1F7ADCF Q28068448-7995B13A-7A4D-4E41-AD6F-407673550E64 Q28071595-713CB27C-70FA-4187-9DFE-D2065635FBA5 Q28550517-277762E2-446B-4FB7-9E26-39D3310C026D Q30238719-84163C69-0FDA-4319-9BF6-8D4F072A2724 Q30239853-8A2C40DE-94F6-4DEE-9BF6-78A95BA7F5A9 Q30252011-DFF5E2C8-7A6B-47DC-A888-D2395AAAFD87 Q30373414-F9B9F16A-05CB-47DA-A4A2-5AAD708F0F74 Q30558959-A00DFA71-2FFA-413B-9F60-73F8F1A7305E Q30573351-62F2D325-CE69-492B-9B61-9F4F8442CF45 Q30644831-FA9B05A6-D8FE-4EE5-9156-63E1B1C2A6A1 Q30884351-B5C4DCA3-2615-4F5D-A763-C4E6FFDEE872 Q33580620-B6769E20-3F95-4A28-AF9F-9D32C0CD95CF Q33647497-468C0B9A-F364-40A0-97E3-E68522EE87E2 Q34019069-B8183694-D8F4-47E0-810A-02AEF7EC129B Q34046881-B1B10B51-8E5F-47A3-8A85-9FCC6F9BFB67 Q34175105-4753861A-2234-426C-9D40-BC24237AA180 Q34282119-D38C7DE1-015B-4C41-BE50-E1661A1F6231 Q34382241-5C9AB6D2-BE36-40E2-A8FD-ABBFCB69FDB7 Q34486065-D74EF08F-513B-4FB1-AF25-4AB6C0C8264C Q34486105-5B814C39-EB56-42DD-B49D-F3FDC8F30A17 Q34486136-A75D4D6C-F3B0-4A07-96D8-7BC3703BEE69 Q34775758-26F42E09-3A07-4615-BCA6-E9505AEC2F30 Q34981539-03EBCA28-9371-4E7F-BC0B-A12F98B8A796 Q35026354-76FDC457-A903-4453-A72C-ECCAA93D0EB8 Q35195203-43F3A19C-C81A-412F-A476-578CA25B5AD2 Q35197451-DDB252F1-A345-4126-B6B8-AC7C81278517 Q35208684-56D57A26-18D7-42B1-885F-65695A0B2D53 Q35216396-4C0E5912-9171-475F-9FFF-FBB89C1B6EF2 Q35353980-8B50B8FE-D92A-4C29-8F08-548F7ECC4BBD Q35544048-007B133B-3101-4028-BB26-606A77FC38B2

P2860

Vorapaxar in the secondary prevention of atherothrombotic events.

http://www.wikidata.org/entity/Q34263311

description

2012 nî lūn-bûn

@nan

2012 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մարտին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Vorapaxar in the secondary prevention of atherothrombotic events.

@ast

Vorapaxar in the secondary prevention of atherothrombotic events.

@en

Vorapaxar in the secondary prevention of atherothrombotic events.

@nl

type

label

Vorapaxar in the secondary prevention of atherothrombotic events.

@ast

Vorapaxar in the secondary prevention of atherothrombotic events.

@en

Vorapaxar in the secondary prevention of atherothrombotic events.

@nl

prefLabel

Vorapaxar in the secondary prevention of atherothrombotic events.

@ast

Vorapaxar in the secondary prevention of atherothrombotic events.

@en

Vorapaxar in the secondary prevention of atherothrombotic events.

@nl

P1433

Q34263311-AE97D8E9-F739-4902-A7D3-6E0AE702B8D8

P1476

Q34263311-01A28D73-24AB-4D58-94AA-F496555A0F1A

P2093

Q34263311-0DBBC781-5C04-408E-AD0C-EFD5FFD854A5

Q34263311-2D3648F4-FEE8-42B3-B0E5-11C65413B8D7

Q34263311-2DCFE66D-77A3-4903-8D53-E4D5DD6FEB5E

Q34263311-3D50DC95-9013-44B6-9E09-84C3CC73E646

Q34263311-44F75B84-6E87-421E-ABFA-C9DEF4C30EDB

Q34263311-4F064048-D746-4067-A94D-36A74D517B01

Q34263311-5C08B857-787F-4F62-A146-03A8B1AE6C2A

Q34263311-63D7583F-38B9-468D-9B47-1C8C8EE18E51

Q34263311-830FBC67-F42E-4931-BC5B-172B05D4C0C1

Q34263311-864A4A0C-739F-4871-9910-4DFFB29D45BB

P304

Q34263311-9E45643A-F5F5-42FB-8175-2ED039BFF98D

P31

Q34263311-0EF72E5A-5D50-49A5-BD23-83E7AA990A1B

P356

Q34263311-80D2D561-FD51-4816-A752-EF0A1E642E8A

P407

Q34263311-C7BDB098-E8EC-455A-AC4C-7AB23123A5B5

P433

Q34263311-20009532-EF24-4C20-A676-323B0FDAF14E

P478

Q34263311-DB4E507A-8F06-4BED-BBC9-B85E65491CBD

P50

Q34263311-767D9E15-0D10-4DE5-BAB7-AEC8E66883B7

P577

Q34263311-4171D121-C77F-43C7-A527-575A01FD90DF

P698

Q34263311-B7C15BAB-C8EF-4124-AEDF-CACDD89F5E52

P356

P1433

The New England Journal of Medicine

P1476

Vorapaxar in the secondary prevention of atherothrombotic events.

@en

P2093

A J Oude Ophuis

http://www.w3.org/2001/XMLSchema#string

Anthony J Dalby

http://www.w3.org/2001/XMLSchema#string

Benjamin M Scirica

http://www.w3.org/2001/XMLSchema#string

David A Morrow

http://www.w3.org/2001/XMLSchema#string

Ernesto Paolasso

http://www.w3.org/2001/XMLSchema#string

Jindrich Spinar

http://www.w3.org/2001/XMLSchema#string

John Strony

http://www.w3.org/2001/XMLSchema#string

José Carlos Nicolau

http://www.w3.org/2001/XMLSchema#string

Keith A A Fox

http://www.w3.org/2001/XMLSchema#string

Leslie J Lipka

http://www.w3.org/2001/XMLSchema#string

P304

1404-1413

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1200933

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

366

http://www.w3.org/2001/XMLSchema#string

P50

Eugene Braunwald

P577

2012-03-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22443427

http://www.w3.org/2001/XMLSchema#string